JamesVredenburghMD

Oncology • Hartford, CT

Professor of Medicine, Duke University

Join to view full profile

Dr. Vredenburgh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vredenburgh's full profile

Already have an account?

Office
114 Woodland St
Hartford, CT 06105
Phone+1 860-714-4680

Fax+1 860-714-8047

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1986 - 1990
University of ConnecticutResidency, Internal Medicine, 1983 - 1986
University of Vermont College of MedicineClass of 1983

Certifications & Licensure

CT State Medical License 1985 - 2025
NC State Medical License 1990 - 2013
VT State Medical License 1988 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas Start of enrollment: 2005 May 01
Completed
Phase 2
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma Start of enrollment: 2006 May 01
Completed
Phase 2
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Start of enrollment: 2006 Apr 01
Completed
Phase 2
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients Start of enrollment: 2004 Feb 01
Completed
Not Applicable
Study of Immunotoxin, MR1-1 Start of enrollment: 2006 Nov 01
Terminated
Phase 1
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

364 citations
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane Mitchell, Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez
Nature. 2015-03-19
575 citations
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Gli...
John H. Sampson, Amy B. Heimberger, Gary E. Archer, Kenneth Aldape, Allan H. Friedman
Journal of Clinical Oncology. 2010-11-01
58 citations
Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.
Leanne Cartee, William P. Petros, Gary L. Rosner, Colleen J. Gilbert, Sarah G. Moore
Cytokine. 1995-07-01

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018